维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="Beuzeboc P"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Multicenter randomized phase Ⅱ study of two schedules of docetaxel,estramustine,and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer显示文摘	Oudard S Banu E Beuzeboc P	2005	J Clin Oncol2005，23，15：	1
2	Targeting HER2 in other tumor types显示文摘	Scholl S Beuzeboc P Pouillart P	2001	Ann Oncol2001，12，1：	1
3	Phase II trial of consolidation docetaxel and samarium 153 in patients with bone metastases from castration resistant prostate eaneer显示文摘	Fizazi K Beuzeboc P Lumbroso J	2009	J Clin Onco12009，27，15：	1
4	Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer显示文摘	LE TOURNEAU C DETTWILER S BEUZEBOC P	2012	Am J Clin Oncol2012，35，3：	1
5	Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer显示文摘	Dorval T Soussain C Beuzeboc P	1996	J Infus Chemother1996，6，1：	1
6	Multicenter randomized phase II study of two schedules of docetaxel, estramustine,and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormonerefraetory prostate cancer显示文摘	Oudard S Banu E Beuzeboc P	2005	J Clin Oncol2005，23，15：	1
7	Targeting HER2 in oth-er tumor types显示文摘	Scholl S Beuzeboc P Pouillart P	2001	Ann Oncol2001，12，：	1
8	Targeting HER2 in other tumor types显示文摘	Scholl S Beuzeboc P Pouillart P	2001	Ann Oncol2001，12，11：	1
9	Targeting HER2 in other tumor types显示文摘	Scholl S Beuzeboc P Pouillart P	2001	Ann Oncol2001，12，1：	1
10	Targeting HER-2 in other tumor types显示文摘	Scholl S Beuzeboc P Pouillart P	2001	Ann Oncol2001，12，1：	1
11	Multicenter randomizedphase It study of two schedules of docetaxel, estramustine, andprednisone versus mitoxantrone plus prednisone in patients withmetastatic hormone-refractory prostate cancer显示文摘	Oudard S Banu E Beuzeboc P et af	2005	J Clin Oncol2005，23，15：	1
12	Targeting Her-2 in other tumor types 显示文摘	Scholl S Beuzeboc P Pouillart P	2001	Ann Oncol2001，12，1：	1
13	Double-blindedcontrolled study comparing clodronate versus placebo in patientswith breast cancer bone metastases显示文摘	Tubiana-Hulin M Beuzeboc P Mauriac L	2001	Bull Cancer2001，88，：	1
14	Herceptin, a monoclonal humanized antibody anti-HER-2: a major therapeutic progress in breast cancers overexpressing this oncogene? 显示文摘	Scholl S Garau XS	1999	Bull Cancer1999，86，6：	1
15	Phase II trial of consolidation docetaxel and samarium-153in patients with bone metastases from castration-resistant prostate cancer显示文摘	Fizazi K Beuzeboc P Lumbroso J	2009	J Clin Oncol2009，27，15：	1
16	Indications of Herceptin in breast cancer treatment显示文摘	Beuzeboc P	2004	Gynecol Obstet Fertil2004，32，2：	1
17	Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases:显示文摘	Tubiana-Hulin M Beuzeboc P Mauriac L	2001	Bull Cancer2001，88，7：	1
18	Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases 显示文摘	Tubiana-Hulin M Beuzeboc P Manriac L	2001	Bulletin Du Cancer2001，88，7：	1
19	Targeting HER-2 in other tumor types显示文摘	Scholl S Beuzeboc P Pouillart P	2001	Ann Oncol2001，12，5：	1
20	Plasminogen activattor inhibitor-1 (PAI-1)is not related to response to neoadjuvant chemotherapy in breast cancer 显示文摘	Pierga JY Laine Bidron C Beuzeboc P	1997	Br J Cancer1997，76，4：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示